Showing results (531-540 of 855) with videos related to
Sort By:
Pageof 86
Current Hematologic Malignancy Reports|February 5, 2020
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell LymphomaLauren Shea, Neha Mehta-ShahCurrent Hematologic Malignancy Reports|December 21, 2019
What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?Robert Peter Gale, Jane ApperleyCurrent Hematologic Malignancy Reports|May 26, 2022
MRD in ALL: Optimization and InnovationsEric Pierce, Benjamin Mautner, Joseph Mort, et al.Current Hematologic Malignancy Reports|May 10, 2022
Targeting Apoptosis in ALLWesley M Smith, Daniel R ReedCurrent Hematologic Malignancy Reports|December 12, 2018
Targeted Therapies in CLL: Monotherapy Versus Combination ApproachesMaliha Khan, Tanya SiddiqiCurrent Hematologic Malignancy Reports|February 24, 2018
Prognostic Factors in the Era of Targeted Therapies in CLLPrajwal Boddu, Alessandra FerrajoliCurrent Hematologic Malignancy Reports|July 5, 2022
Germline and Somatic Defects in DDX41 and its Impact on Myeloid NeoplasmsTalha Badar, Timothy ChlonCurrent Hematologic Malignancy Reports|January 7, 2021
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?Tamer Othman, Alex Herrera, Matthew MeiCurrent Hematologic Malignancy Reports|February 13, 2020
Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health SpanShimoli V Barot, Bhumika J Patel, Aaron T GerdsCurrent Hematologic Malignancy Reports|January 7, 2014
PI3-kinase inhibitors in chronic lymphocytic leukemiaJulie E Chang, Brad S KahlPageof 86